Disposition of 21258 shares by Oliviero James F Iii of Checkpoint Therapeutics at 1.51 subject to Rule 16b-3
| CKPT Stock | USD 3.00 0.05 1.69% |
Slightly above 51% of Checkpoint Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Checkpoint Therapeutics suggests that some traders are interested. Checkpoint Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Checkpoint Therapeutics' earnings reports, geopolitical events, and overall market trends.
Checkpoint |
Filed transaction by Checkpoint Therapeutics Director, Officer Ceo, President And Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Checkpoint Therapeutics Fundamental Analysis
We analyze Checkpoint Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Checkpoint Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Checkpoint Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Checkpoint Therapeutics is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Checkpoint Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Checkpoint Therapeutics stock to make a market-neutral strategy. Peer analysis of Checkpoint Therapeutics could also be used in its relative valuation, which is a method of valuing Checkpoint Therapeutics by comparing valuation metrics with similar companies.
Peers
Checkpoint Therapeutics Related Equities
| CUE | Cue Biopharma | 14.88 | ||||
| CTMX | CytomX Therapeutics | 3.57 | ||||
| ATXI | Avenue Therapeutics | 2.72 | ||||
| ACHL | Achilles Therapeutics | 1.75 | ||||
| FBIOP | Fortress Biotech | 1.14 | ||||
| RVPH | Reviva Pharmaceuticals | 1.06 | ||||
| FBIO | Fortress Biotech | 0.55 | ||||
| XOMAO | XOMA | 0.28 | ||||
| ASMB | Assembly Biosciences | 0.67 | ||||
| MBIO | Mustang Bio | 1.92 | ||||
| TIL | Instil Bio | 2.86 | ||||
| SPRO | Spero Therapeutics | 3.33 | ||||
| KOD | Kodiak Sciences | 3.61 |
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.